Treatment of patients with hypertension who are infected with the severe acute respiratory syndrome coronavirus 2 with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers may improve clinical outcomes.
Wearable technologies that include digital and automated health, as well as telehealth, are expected to be well integrated into cardiovascular care in the next 5 years.
The Food and Drug Administration approved the 50cc temporary Total Artificial Heart System developed and manufactured by SynCardia Systems, LLC as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
For the first time in the United States, titanium bone-anchored implants were used to repair large annular defects during diskectomies.
The US Food and Drug Administration is seeking feedback from healthcare professionals on its proposal to offer fixed-quantity blister packaging for a select number of opioid medications.
